• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PEDIATRIC HSCT-TMA
    • GEOGRAPHIC ATROPHY (GA)
  • THE SCIENCE
    • Close
    • OVERVIEW
    • MODE OF ACTION
    • TARGET PATHWAYS
      • Close
      • C5 (COMPLEMENT SYSTEM)
      • LTB4 (LEUKOTRINE SYSTEM)
    • MOLECULES
      • Close
      • NOMACOPAN
      • OTHER NOMACOPAN-BASED MOLECULES
      • VOTUCALIS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & EVENTS
      • Close
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • INVESTOR RESOURCES
      • Close
      • INVESTOR FAQS
      • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • PUBLICATIONS
    • STORIES
  • CONTACT US

Press Release

Akari TX / May 16, 2023

Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference

NEW YORK and LONDON, May 16, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference

Akari TX / May 1, 2023

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

NEW YORK and LONDON, May 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Akari TX / April 25, 2023

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Akari TX / April 14, 2023

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

NEW YORK and LONDON, April 14, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Akari TX / April 11, 2023

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Next Page »

Footer

Akari TX

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

1460 Broadway
New York, NY 10036

T: 929.274.7510
F: 929.274.7553
E: info@Akaritx.com

For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com

REGISTERED ADDRESS

Akari Therapeutics, Plc is registered in England and Wales under number 5252842 and has its registered office at Highdown House, Yeoman Way, Worthing, West Sussex, BN99 3HH.

EXPANDED ACCESS POLICY

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access.  At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Copyright © 2023 · Akari Therapeutics · Site Designed by Polus Digital, Inc.